tiprankstipranks
Trending News
More News >
Innate Pharma SA (IPHYF)
OTHER OTC:IPHYF
US Market

Innate Pharma SA (IPHYF) Income Statement

Compare
27 Followers

Innate Pharma SA Income Statement

Last quarter (Q4 2024), Innate Pharma SA's total revenue was €4.33M, a decrease of -47.90% from the same quarter last year. In Q4, Innate Pharma SA's net income was €-24.71M. See Innate Pharma SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
€ 12.62M€ 51.90M€ 49.64M€ 12.11M€ 69.77M
Gross Profit
€ 0.00€ -4.12M€ -2.02M€ -34.89M€ 20.07M
Operating Expenses
€ 69.70M€ 64.57M€ 66.06M€ 59.94M€ 18.99M
Depreciation and Amortization
€ 1.99M€ 5.09M€ 4.42M€ 4.57M€ 12.23M
EBITDA
€ -50.99M€ -7.58M€ -61.30M€ -43.23M€ 13.30M
Operating Income
€ -59.07M€ -12.67M€ -11.65M€ -47.83M€ 1.08M
Other Income/Expenses
€ 2.12M€ 5.10M€ -547.00K€ 2.35M€ -1.91M
Pretax Income
€ -56.96M€ -7.57M€ -57.97M€ -45.48M€ -829.00K
Net Income
€ -49.47M€ -7.57M€ -99.10M€ -59.14M€ -63.98M
Per Share Metrics
Basic EPS
€ -0.61€ -0.09€ -1.24€ -0.74€ -0.01
Diluted EPS
€ -0.61€ -0.09€ -1.24€ -0.74€ -0.01
Weighted Average Shares Outstanding
81.05M 80.45M 79.64M 79.54M 6.09B
Weighted Average Shares Outstanding (Diluted)
81.05M 80.45M 79.64M 79.54M 78.93M
Currency in EUR

Innate Pharma SA Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis